GILD is the one that grabbed all of the attention because so many people may be on the drug. But it really could be considered cost-effective IMO.....not this one though. ZAP3 coming soon. t
your post fails to realize that orphan drugs are given leniency both on approval and are on pricing because they treat rare conditions. GIld's Sovaldi does not treat a disease that has 15k patients worldwide like AEGR does.
Your post fails to understand that the price is fodder for Congress. And you do have now over 49% potential return. Good luck. t